Lifemd, Inc. (LFMDP) Stock Price & Analysis

Lifemd, Inc. (LFMDP) rose 1.06% to USD 23.5 as of September 8, 2026 at 21:33 UTC, according to Nexqual real-time market data.

LFMDP last closed at USD 23.5; the session ranged USD 23.5–23.59 on volume of 1,408 shares. Market capitalization is —, with a 52-week range of USD 18.5–24.2 (NGM). Source: Nexqual, September 8, 2026 at 21:33 UTC.

Key Statistics (as of September 8, 2026 at 21:33 UTC)

Technical Analysis (LFMDP)

Nexqual's technical model rates LFMDP "STRONG BUY" based on 5 bullish and 0 bearish signals across 127 daily candles, as of September 8, 2026 at 21:33 UTC.

From Lifemd, Inc.'s Latest SEC 10-K Filing (filed 2026-03-10)

Key Strengths & Strategy (as disclosed to the SEC)

• Approximately 95% of our total revenue is derived from recurring subscriptions.   Our End-to-End Telehealth Platform   LifeMD has developed a proprietary, fully integrated telehealth and pharmacy platform designed to support diagnosis, treatment, prescription fulfillment, and ongoing care management within a unified ecosystem.
• Our human capital and know-how, proprietary technology platform, and unique product offerings represent meaningful strengths that we believe will enable us to maintain and grow our market-leading position in the U.S.    Our key competitive strengths include:     Discontinued Operations   On November 4, 2025, we sold our majority ownership interest in WorkSimpli to Lion Buyer, LLC.
• At the same time, the United States ("U.S.") continues to experience shortages in primary care key specialty areas.   Through our vertically integrated care model, we combine proprietary technology, affiliated clinical services, pharmacy infrastructure, and artificial intelligence ("AI")-enabled operational systems to deliver longitudinal care at scale.
• As of December 31, 2025, our network covered approximately 112 million lives, including approximately 30 million Medicare Fee-for-Service beneficiaries.

Partnerships

• We entered into a management services agreement with LifeMD PC pursuant to which we provide them with billing, scheduling and a wide range of other services, and they pay us for those services.
• Secondly, we have partnered with an AI-powered platform that optimizes prior authorization submissions and aims to improve approval rates for patients.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 21:33 UTC. This page is informational and not investment advice.